BioMarin Pays $70M Upfront for Second Fabry Disease Therapy
BMRN is trading near its 52-week low of $49.259 (14% above the low).
Summary
BioMarin is licensing HM15421/GC1134A, an investigational next-generation enzyme replacement therapy for Fabry disease, from GC Biopharma and Hanmi Pharm on an exclusive worldwide basis outside Korea. It pays $70 million upfront, with the partners eligible for up to $405 million in milestones and royalties; GC and Hanmi keep commercialization rights in Korea while BioMarin takes sole responsibility elsewhere. The deal adds a second potential Fabry treatment to a portfolio that already includes its marketed enzyme replacement therapy, extending the rare-disease franchise rather than opening a new one. The upfront is modest against a company of this size, but the milestone structure ties most of the payout to clinical and commercial success. This follows the August Alesta Therapeutics acquisition and the October 6th disclosure of a $283 million Q3 IPR&D charge tied to that deal — BioMarin is clearly still shopping for pipeline assets. Q3 results will show whether the string of deal-related charges is pressuring EPS.
At the time of this announcement, BMRN was trading at $56.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.8B. The 52-week trading range was $49.26 to $70.98. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.